GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

Snoring, often dismissed as a minor issue, actually signals restricted airflow during sleep. Factors like blocked nasal ...

Know when inhalers actually help blocked nose relief, when they can worsen congestion, and common mistakes doctors warn ...

Insmed Inc. shares sunk in late trading Wednesday after the company said its drug to treat a sinus condition failed in a mid-stage trial — a rare setback for the fast-growing biotech.

Drug trials offer people with cancer hope and free medicine, but they also create incentives for doctors in private clinics to sign up patients for unproven treatments ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Insmed has come up short in its attempt to expand its newly approved potential blockbuster Brinsupri into a new indication. | With the failure of a phase 2 trial of Brinsupri in chronic rhinosinusitis ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for another condition, the drugmaker said on Tuesday.